Your browser doesn't support javascript.
loading
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
Gonçalves, Emanuel; Segura-Cabrera, Aldo; Pacini, Clare; Picco, Gabriele; Behan, Fiona M; Jaaks, Patricia; Coker, Elizabeth A; van der Meer, Donny; Barthorpe, Andrew; Lightfoot, Howard; Mironenko, Tatiana; Beck, Alexandra; Richardson, Laura; Yang, Wanjuan; Lleshi, Ermira; Hall, James; Tolley, Charlotte; Hall, Caitlin; Mali, Iman; Thomas, Frances; Morris, James; Leach, Andrew R; Lynch, James T; Sidders, Ben; Crafter, Claire; Iorio, Francesco; Fawell, Stephen; Garnett, Mathew J.
Affiliation
  • Gonçalves E; Wellcome Sanger Institute, Hinxton, UK.
  • Segura-Cabrera A; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK.
  • Pacini C; Wellcome Sanger Institute, Hinxton, UK.
  • Picco G; Wellcome Sanger Institute, Hinxton, UK.
  • Behan FM; Wellcome Sanger Institute, Hinxton, UK.
  • Jaaks P; Wellcome Sanger Institute, Hinxton, UK.
  • Coker EA; Wellcome Sanger Institute, Hinxton, UK.
  • van der Meer D; Wellcome Sanger Institute, Hinxton, UK.
  • Barthorpe A; Wellcome Sanger Institute, Hinxton, UK.
  • Lightfoot H; Wellcome Sanger Institute, Hinxton, UK.
  • Mironenko T; Wellcome Sanger Institute, Hinxton, UK.
  • Beck A; Wellcome Sanger Institute, Hinxton, UK.
  • Richardson L; Wellcome Sanger Institute, Hinxton, UK.
  • Yang W; Wellcome Sanger Institute, Hinxton, UK.
  • Lleshi E; Wellcome Sanger Institute, Hinxton, UK.
  • Hall J; Wellcome Sanger Institute, Hinxton, UK.
  • Tolley C; Wellcome Sanger Institute, Hinxton, UK.
  • Hall C; Wellcome Sanger Institute, Hinxton, UK.
  • Mali I; Wellcome Sanger Institute, Hinxton, UK.
  • Thomas F; Wellcome Sanger Institute, Hinxton, UK.
  • Morris J; Wellcome Sanger Institute, Hinxton, UK.
  • Leach AR; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK.
  • Lynch JT; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Sidders B; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Crafter C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Iorio F; Wellcome Sanger Institute, Hinxton, UK.
  • Fawell S; Human Technopole, Milano, Italy.
  • Garnett MJ; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA.
Mol Syst Biol ; 16(7): e9405, 2020 07.
Article in En | MEDLINE | ID: mdl-32627965
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Screening Assays, Antitumor / Gene Regulatory Networks / Genetic Fitness / Protein Interaction Maps / CRISPR-Cas Systems / Drug Development / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Mol Syst Biol Journal subject: BIOLOGIA MOLECULAR / BIOTECNOLOGIA Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Screening Assays, Antitumor / Gene Regulatory Networks / Genetic Fitness / Protein Interaction Maps / CRISPR-Cas Systems / Drug Development / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Mol Syst Biol Journal subject: BIOLOGIA MOLECULAR / BIOTECNOLOGIA Year: 2020 Document type: Article Affiliation country: Country of publication: